Latest Conference Articles

February 10th 2021, 10:23pm

Transplantation and Cellular Therapy Meetings

February 10, 2021 - Hematopoietic recovery following myeloablative transplantation with omidubicel was faster than standard myeloablative umbilical cord blood transplantation and was associated with encouraging clinical benefit.

February 10th 2021, 9:47pm

Transplantation and Cellular Therapy Meetings

Anna Barata, PhD, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel) in patients 1-year post-infusion.

February 10th 2021, 9:42pm

Transplantation and Cellular Therapy Meetings

YunZu Michele Wang, MD, discusses the potential utility of ruxolitinib in children and young adult patients with chronic graft-versus-host disease.

February 10th 2021, 9:35pm

Transplantation and Cellular Therapy Meetings

February 10, 2021 - Treatment with the investigative gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients less than 18 years of age with transfusion-dependent beta-thalassemia with a median average hemoglobin of 11.3 g/dL.

February 10th 2021, 5:22pm

Transplantation and Cellular Therapy Meetings

February 10, 2021 - CPX-351 demonstrated improved overall survival at 5 years versus standard 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

February 10th 2021, 4:52pm

Transplantation and Cellular Therapy Meetings

February 10, 2021 - The JAK 1/2 inhibitor ruxolitinib, when given at a maximum dose of 10 mg peri-transplant, has been shown to be safe and feasible in patients with myelofibrosis.

February 9th 2021, 10:05pm

Transplantation and Cellular Therapy Meetings

February 9, 2021 - Responsiveness to treatment received immediately prior to CAR T-cell therapy may not be associated with post–CAR T outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma who receive axicabtagene ciloleucel.

February 9th 2021, 10:00pm

Transplantation and Cellular Therapy Meetings

Sairah Ahmed, MD, discusses the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory large B-cell lymphoma (LBCL) who achieved complete remission (CR) to any prior treatment versus those who were primary refractory.

February 9th 2021, 10:00pm

Transplantation and Cellular Therapy Meetings

Mitchell E. Horwitz, MD, discusses the use of omidubicel versus standard myeloablative umbilical cord blood transplant in patients with hematologic malignancies.

February 9th 2021, 7:45pm

Transplantation and Cellular Therapy Meetings

February 9, 2021 - Patients with refractory large B-cell lymphoma have less to gain from axicabtagene ciloleucel if they have never achieved a complete response to any line of prior therapy.

February 9th 2021, 7:42pm

Transplantation and Cellular Therapy Meetings

February 9, 2021 - Ruxolitinib, when administered using a pediatric dosing algorithm, was found to elicit responses in patients with chronic graft-versus-host disease with acceptable safety.

February 9th 2021, 2:56pm

Transplantation and Cellular Therapy Meetings

February 9, 2021 - JSP191 in combination with low-dose total body irradiation and fludarabine has demonstrated efficacy and tolerability in older patients with minimal residual disease–positive acute myeloid leukemia and myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.

February 9th 2021, 12:30am

Transplantation and Cellular Therapy Meetings

February 8, 2021 — Narsoplimab demonstrated clinical activity and a favorable survival benefit in patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy, according to updated results of a pivotal phase 2 trial.

February 8th 2021, 11:10pm

PER® Winter Lung Cancer Conference

With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.

February 8th 2021, 10:44pm

PER® Winter Lung Cancer Conference

Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.

February 8th 2021, 10:41pm

PER® Winter Lung Cancer Conference

Luis E. Raez, MD, discusses the potential utility of cemiplimab-rwlc in non–small cell lung cancer.

February 8th 2021, 9:38pm

PER® Winter Lung Cancer Conference

Vincent Lam, MD, describes frontline indications for this patient population, as well as strategies that can be utilized to overcome TKI resistance in later lines of therapy.

February 8th 2021, 7:45pm

Transplantation and Cellular Therapy Meetings

February 8, 2021 - Prior exposure to anti-CD19 therapy did not impact response to the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

February 8th 2021, 5:32pm

Transplantation and Cellular Therapy Meetings

February 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and non-SARS human coronaviruses.

February 7th 2021, 9:00pm

PER® Winter Lung Cancer Conference

Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients.